Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.
Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.
This analysis was not as stringent as a conventional clinical trial, Yardley says, and aimed to evaluate patients treated with T-DM1 in the community setting. In this trial, patients received a median of 8 prior therapies and were able to receive T-DM1 before its FDA approval.
The time from initial metastatic diagnosis to receiving T-DM1 in this trial was a mean of 42 months, Yardley says, which is astounding and highlights the benefit of HER2-targeted therapies. Among patients who remained on T-DM1 for over a year, median time from diagnosis to T-DM1 was 60 months. This as well reinforces the advancements of HER2-targeted therapies, Yardley says.
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More